[Therapeutic conclusions from the immunologic events in agranulocytosis].
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D000667:Ampicillin / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001463:Barbiturates / Q000009:adverse effects; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000150:complications / Q000188:drug therapy; D003091:Colistin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007110:Immunity, Active; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use; D010118:Oxytetracycline / Q000627:therapeutic use; D010400:Penicillin G / Q000627:therapeutic use; D010567:Pertussis Vaccine / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects; D011239:Prednisolone / Q000627:therapeutic use; D005719:gamma-Globulins / Q000627:therapeutic use
D000935:Antifungal Agents; D001463:Barbiturates; D010567:Pertussis Vaccine; D005719:gamma-Globulins; D010672:Phenytoin; D000667:Ampicillin; D011239:Prednisolone; D009355:Neomycin; D010400:Penicillin G; D010118:Oxytetracycline; D003091:Colistin
Therapeutische Schlussfolgerungen aus dem immunologischen Gescheben bei Agranulozytose.